So proud of the @vigeotx.bsky.social Team on the publication of our First in Human Phase 1 study with VT1021 in #NatureCommunicationsMedicine This paper is a great achievement showing the power of VT1021 treating solid tumors #CD36 #CD47 #VT1021 #NaturePortfolio
rdcu.be/dvUw8
0
0
0
0